Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.

Alessandra Fiorio Pla 1, 2 Alessia Brossa 3 Michela Bernardini 2 Tullio Genova 2 Guillaume Grolez 1 Arnaud Villers 4 Xavier Leroy 5 Natalia Prevarskaya 1 Dimitra Gkika 1 Benedetta Bussolati 3, *
* Auteur correspondant
1 Rôle des canaux ioniques membranaires et du calcium intracellulaire dans la physiopathologie de la prostate
2 Dipartimento di Scienze della Vita e Biologia dei Sistemi
3 Molecular Biotechnology Center
4 Service Urologie
5 Service d'anatomopathologie
Abstract : Prostate cancer is the second leading cause of male cancer death in developed countries. Although the role of angiogenesis in its progression is well established, the efficacy of anti-angiogenic therapy is not clearly proved. Whether this could depend on differential responses between tumor and normal endothelial cells has not been tested. We isolated and characterized three lines of endothelial cells from prostate cancer and we tested the effect of Sunitinib and Sorafenib, and the combined treatment with the anti-androgen Casodex, on their angiogenic functions. Endothelial cells isolated from prostate tumors showed angiogenic properties and expression of androgen and vascular endothelial cell growth factor receptors. Sunitinib affected their proliferation, survival and motility while Sorafenib only showed a minor effect. At variance, Sunitinib and Sorafenib showed similar cytotoxic and anti-angiogenic effects on normal endothelial cells. Sorafenib and Sunitinib inhibited vascular endothelial cell growth factor receptor2 phosphorylation of prostate cancer endothelial cells, while they differentially modulated Akt phosphorylation as no inhibitory effect of Sorafenib was observed on Akt activation. The combined treatment of Casodex reverted the observed resistance to Sorafenib both on cell viability and on Akt activation, whereas it did not modify the response to Sunitinib. Our study demonstrates a resistant behavior of endothelial cells isolated from prostate cancer to Sorafenib, but not Sunitinib. Moreover, it shows the benefit of a multi-target therapy combining anti-angiogenic and anti-hormonal drugs to overcome resistance.
Keywords : Anti-angiogenic therapy VEGF receptor Androgen receptor Prostate cancer Drug resistance
Type de document :
Article dans une revue
BMC Cancer, BioMed Central, 2013, 14 (1), pp.939
Liste complète des métadonnées

Littérature citée [42 références]  Voir  Masquer  Télécharger
http://www.hal.inserm.fr/inserm-01122893
Contributeur : Nadia Taibi <>
Soumis le : mercredi 4 mars 2015 - 17:30:33
Dernière modification le : lundi 9 mars 2015 - 15:36:06
Document(s) archivé(s) le : vendredi 5 juin 2015 - 11:17:10

Fichier

1471-2407-14-939.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Collections

Citation

Alessandra Fiorio Pla, Alessia Brossa, Michela Bernardini, Tullio Genova, Guillaume Grolez, et al.. Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.. BMC Cancer, BioMed Central, 2013, 14 (1), pp.939. 〈inserm-01122893〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

69

Téléchargements de fichiers

46

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD